Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

被引：11
|
作者：
Chan, Onyee [1 ,2 ]
Hunter, Anthony [1 ,2 ]
Talati, Chetasi [1 ]
Sallman, David A. [1 ,3 ]
Asghari, Hannah [1 ,2 ]
Song, Jinming [4 ]
Hussaini, Mohammad [4 ]
Bejanyan, Nelli [5 ]
Elmariah, Hany [5 ]
Kuykendall, Andrew T. [1 ]
Padron, Eric [2 ]
Komrokji, Rami S. [1 ,3 ,6 ]
List, Alan F. [1 ]
Lancet, Jeffrey E. [1 ]
Sweet, Kendra L. [1 ]
Mishra, Asmita [5 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
[2] Univ S Florida, Dept Med, Tampa, FL 33620 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat & Cellular Immun, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
149
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Impact of prior solid tumor on outcomes of allogeneic hematopoietic stem cell transplantation for AML or MDS.
    Albittar, Aya
    Portuguese, Andrew Jay
    Gooley, Ted
    Deeg, H. Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation
    Heuser, Michael
    Koenecke, Christian
    Gabdoulline, Razif
    Loeffeld, Patrick
    Dobbernack, Vera
    Panagiota, Victoria
    Klesse, Sabrina
    Stadler, Michael
    Krauter, Juergen
    Dammann, Elke
    Wichmann, Martin
    Shahswar, Rabia
    Bhuju, Sabin
    Geffers, Robert
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Kleine, Moritz
    Brauns, Wiebke
    Platzbecker, Uwe
    Thiede, Christian
    Schroeder, Thomas
    Kobbe, Guido
    Ganser, Arnold
    Kroeger, Nicolaus
    Thol, Felicitas
    BLOOD, 2015, 126 (23)
  • [23] Impact of cytogenetics and prior therapy on outcome of AML and MDS after allogeneic transplantation.
    Armand, Philippe
    Kim, Haesook T.
    DeAngelo, Daniel J.
    Ho, Vincent T.
    Cutler, Corey S.
    Stone, Richard M.
    Ritz, Jerome
    Alyea, Edwin P.
    Antin, Joseph H.
    Soiffer, Robert J.
    BLOOD, 2006, 108 (11) : 80A - 81A
  • [24] Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC)
    Hemmati, Philipp
    Massenkeil, Gero
    Terwey, Theis
    Neuburger, Stefan
    le Coutre, Philipp D.
    Vuong, Lam G.
    Doerken, Bernd
    Arnold, Renate
    BLOOD, 2008, 112 (11) : 1126 - 1126
  • [25] Impact of prior invasive pulmonary aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation
    El-Cheikh, J.
    Wang, L.
    Faucher, C.
    Furst, S.
    Esterni, B.
    Berger, P.
    Blaise, D.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S249 - S249
  • [26] Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with MDS or secondary AML
    Kröger, N
    Schwerdtfeger, R
    Bornhäuser, M
    Ehninger, G
    Runde, V
    Beyer, J
    Kiehl, M
    Schetelig, J
    Siegert, W
    Schäfer-Eckert, K
    Wandt, H
    Sayer, HG
    Kröger, M
    Zabelina, T
    Zander, AR
    BONE MARROW TRANSPLANTATION, 2002, 29 : S57 - S57
  • [27] Presence of TP53 Mutation and Monosomal Karyotype Predict the Outcome of Patients with Acute Myeloid Leukemia in Non-Remission at Allogeneic Stem Cell Transplantation
    Najima, Yuho
    Sadato, Daichi
    Harada, Yuka
    Hirama, Chizuko
    Oboki, Keisuke
    Toya, Takashi
    Doki, Noriko
    Haraguchi, Kyoko
    Yoshifuji, Kota
    Akiyama, Megumi
    Inamoto, Kyoko
    Igarashi, Aiko
    Kobayashi, Takeshi
    Kakihana, Kazuhiko
    Okuyama, Yoshiki
    Sakamaki, Hisashi
    Harada, Hironori
    Ohashi, Kazuteru
    BLOOD, 2018, 132
  • [28] FLUDARABINE AND TREOSULFAN CONDITIONING FOR ALLOGENEIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH AML AND MDS NOT ELIGIBLE FOR STANDARD MYELOABLATIVE CONDITIONING
    Shimoni, A.
    Crotta, A.
    Shem-Tov, N.
    Peccatori, J.
    Yerushalmi, R.
    Bernardi, M.
    Nagler, A.
    Ciceri, F.
    HAEMATOLOGICA, 2012, 97 : 177 - 177
  • [29] Busulfan Does Intensity and Outcomes in Reduced Intensity Allogeneic Stem Cell Transplantation for MDS/AML
    Chen, Yi-Bin
    Coughlin, Erin
    Cutler, Corey
    Kennedy, Kevin
    Alyea, Edwin P., III
    Armand, Philippe
    Attar, Eyal C.
    Ballen, Karen
    Dey, Bimalangshu R.
    Koreth, John
    McAfee, Steven L.
    Spitzer, Thomas R.
    Antin, Joseph H.
    Soiffer, Robert J.
    Ho, Vincent T.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S114 - S115
  • [30] TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
    Zhao, Davidson
    Zarif, Mojgan
    Zhou, Qianghua
    Capo-Chichi, Jose-Mario
    Schuh, Andre
    Minden, Mark D.
    Atenafu, Eshetu G.
    Kumar, Rajat
    Chang, Hong
    CANCERS, 2023, 15 (12)
12345